Jul 2026· Molecular and Cellular Biochemistry· Vol 481, pp. 3999 - 4013· 0 citations· 38 references
Medicine
TL;DR
A novel METTL3/TRIM37/CAV1 regulatory axis that represents an important pathway contributing to NAFLD exacerbation is unveiled and Restoring CAV1 expression represents a promising therapeutic strategy for NAFLD.
Abstract Objectives Non-alcoholic fatty liver disease (NAFLD) exhibits a high prevalence globally. The pathogenesis of NAFLD is complex, and an increasing number of studies have indicated that dysregulation of miRNAs is implicated in this process. The aim of this study is to elucidate the function and regulatory mechan...
BACKGROUND AND AIM
Chronic liver injury-induced liver fibrosis, if left untreated, can progress to cirrhosis or hepatocellular carcinoma, posing a serious threat to human health. Our previous study demonstrated that the natural product demethylzeylasteral (T-96) alleviates liver fibrosis by suppressing ArfGAP with GTPa...
Cheng-Long Wu, Jie Gao, Bo Gao et al.· Journal of Gastroenterology...· 0 citations
Background & Aims Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of chronic liver disease, and liver fibrosis is the principal determinant of disease progression and clinical outcome. We recently showed that non-apoptotic caspase-8 in hepatocytes is upregulated in MASH and leads to the induc...
Xiao-Bo Wang, Eui-Jung Jung, Lanuza A. P. Faccioli et al.· bioRxiv· 0 citations
Findings support a harmful role of essential fatty acids depletion fomenting liver inflammation and identify DNL as a major culprit of steatohepatitis induced by constitutive PI3K-AKT activation.
Á. Peixoto, Érique Castro, Bianca F. Leonardi et al.· bioRxiv· 0 citations
Liraglutide demonstrated the ability to mitigate lipid accumulation, oxidative stress, and iron overload in HepG2 cells subjected to FFA-induced injury, suggesting a mechanistic basis for the potential protective role of liraglutide in MASLD.
J. Bai, Y. Xiao, P. Lou et al.· Physiological Research· 0 citations
BACKGROUND
Liver fibrosis (LF) lacks effective therapies. Longevity assurance homolog 2 (LASS2), a key ceramide synthase, contributes to liver homeostasis, but its role in LF remain unclear.
METHODS
Bioinformatics revealed LASS2 correlation with classic fibrotic factors, and its expression was assessed in fibrotic mo...
